{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T00:33:40Z","timestamp":1759624420462,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011583","name":"Kansas Academy of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011583","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.exphem.2022.09.002","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T04:53:54Z","timestamp":1663736034000},"page":"44-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia"],"prefix":"10.1016","volume":"115","author":[{"given":"Faezeh","family":"Darbaniyan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7829-5249","authenticated-orcid":false,"given":"Rashmi","family":"Kanagal-Shamanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Lockyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Montalban-Bravo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6874-7413","authenticated-orcid":false,"given":"Marcos","family":"Estecio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly A.","family":"Soltysiak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6024-1613","authenticated-orcid":false,"given":"Kelly S.","family":"Chien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3130-3613","authenticated-orcid":false,"given":"Caleb","family":"Class","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Ganan-Gomez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim-Anh","family":"Do","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2288-8405","authenticated-orcid":false,"given":"Yue","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2022.09.002_bib0001","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.09.002_bib0002","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.exphem.2022.09.002_bib0003","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ajh.23642","article-title":"Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management","volume":"89","author":"Garcia-Manero","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2022.09.002_bib0004","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1470-2045(16)00009-7","article-title":"Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial","volume":"17","author":"Garcia-Manero","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.exphem.2022.09.002_bib0005","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1002\/cncr.25247","article-title":"Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy","volume":"116","author":"Jabbour","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2022.09.002_bib0006","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1182\/blood-2014-06-582809","article-title":"TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients","volume":"124","author":"Bejar","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.09.002_bib0007","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1172\/JCI78752","article-title":"Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia","volume":"125","author":"Meldi","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2022.09.002_bib0008","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.exphem.2013.12.004","article-title":"Mechanisms of resistance to azacitidine in human leukemia cell lines","volume":"42","author":"Sripayap","year":"2014","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2022.09.002_bib0009","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.celrep.2017.06.067","article-title":"Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes","volume":"20","author":"Unnikrishnan","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.exphem.2022.09.002_bib0010","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1182\/blood-2018-03-785915","article-title":"How I treat MDS after hypomethylating agent failure","volume":"133","author":"Santini","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.09.002_bib0011","doi-asserted-by":"crossref","first-page":"R36","DOI":"10.1186\/gb-2013-14-4-r36","article-title":"TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions","volume":"14","author":"Kim","year":"2013","journal-title":"Genome Biol"},{"key":"10.1016\/j.exphem.2022.09.002_bib0012","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"10.1016\/j.exphem.2022.09.002_bib0013","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.exphem.2022.09.002_bib0014","doi-asserted-by":"crossref","first-page":"D691","DOI":"10.1093\/nar\/gkq1018","article-title":"Reactome: a database of reactions, pathways and biological processes","volume":"39","author":"Croft","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.exphem.2022.09.002_bib0015","doi-asserted-by":"crossref","first-page":"18416","DOI":"10.1073\/pnas.1906251116","article-title":"The GABA receptor GABRR1 is expressed on and functional in hematopoietic stem cells and megakaryocyte progenitors","volume":"116","author":"Zhu","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.exphem.2022.09.002_bib0016","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1182\/blood-2004-01-0373","article-title":"Primary human CD34+ hematopoietic stem and progenitor cells express functionally active receptors of neuromediators","volume":"104","author":"Steidl","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.09.002_bib0017","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/s41375-019-0623-5","article-title":"Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes","volume":"34","author":"Montalban-Bravo","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2022.09.002_bib0018","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/CCO.0b013e328313699c","article-title":"Demethylating agents in myeloid malignancies","volume":"20","author":"Garcia-Manero","year":"2008","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.exphem.2022.09.002_bib0019","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/leu.2011.71","article-title":"Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias","volume":"25","author":"Itzykson","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2022.09.002_bib0020","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1182\/blood-2009-02-203547","article-title":"Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies","volume":"114","author":"Fandy","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2022.09.002_bib0021","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1158\/0008-5472.CAN-19-1696","article-title":"Activation of a subset of evolutionarily young transposable elements and innate immunity are linked to clinical responses to 5-azacytidine","volume":"80","author":"Ohtani","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.exphem.2022.09.002_bib0022","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nature06494","article-title":"Identification of RPS14 as a 5q\u2013 syndrome gene by RNA interference screen","volume":"451","author":"Ebert","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2022.09.002_bib0023","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/nm.4047","article-title":"Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9","volume":"22","author":"Schneider","year":"2016","journal-title":"Nat Med"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X2200697X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X2200697X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:37:31Z","timestamp":1759567051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X2200697X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":23,"alternative-id":["S0301472X2200697X"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2022.09.002","relation":{},"ISSN":["0301-472X"],"issn-type":[{"type":"print","value":"0301-472X"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2022.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of ISEH -- Society for Hematology and Stem Cells.","name":"copyright","label":"Copyright"}]}}